Vernalis plc (VNLPY) Receives Average Rating of “Strong Buy” from Brokerages
Shares of Vernalis plc (NASDAQ:VNLPY) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Zacks has also assigned Vernalis plc an industry rank of 99 out of 265 based on the ratings given to its competitors.
Separately, Stifel Nicolaus restated a “buy” rating on shares of Vernalis plc in a research note on Saturday, June 25th.
Shares of Vernalis plc (NASDAQ:VNLPY) remained flat at $1.09 during trading on Wednesday. The stock’s market cap is $286.78 million. Vernalis plc has a 12 month low of $1.09 and a 12 month high of $2.43. The stock’s 50 day moving average is $1.09 and its 200 day moving average is $1.24.
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.